Hypoparathyroidism Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Hypoparathyroidism pipeline constitutes 10+ key companies continuously working towards developing 10+ Hypoparathyroidism treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Hypoparathyroidism Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hypoparathyroidism Market.

The Hypoparathyroidism Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Hypoparathyroidism Pipeline Report: https://www.delveinsight.com/sample-request/hypoparathyroidism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Hypoparathyroidism treatment therapies with a considerable amount of success over the years.
• Hypoparathyroidism companies working in the treatment market are Ascendis Pharma, Bridgebio/Calcilytix Therapeutics, Amolyt Pharma, MBX Bioscience, Amorphical Ltd., Entera Bio Ltd., Visen Pharmaceuticals, and others, are developing therapies for the Hypoparathyroidism treatment
• Emerging Hypoparathyroidism therapies in the different phases of clinical trials are- TRANSCON PTH (palopegteriparatide), Encaleret (BBP-305/CLTX-305), AZP-3601 (eneboparatide), MBX 2109, AMOR-1, EBP05, TransCon PTH, and others are expected to have a significant impact on the Hypoparathyroidism market in the coming years.
• In March 2026, MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of innovative precision peptide therapies for endocrine and metabolic disorders, announced the successful completion of an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA). The meeting focused on discussing the overall design of the Phase 3 clinical trial for once-weekly canvuparatide in the treatment of chronic hypoparathyroidism (HP).
• In September 2025, BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio"), a biopharmaceutical company specializing in genetic diseases, announced that encaleret achieved PTH-independent normalization of blood and urine calcium in patients with post-surgical hypoparathyroidism. The Phase 2 results were presented orally at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2025.
• In September 2025, MBX Biosciences is progressing its hypoparathyroidism therapy after 63% of patients met the primary endpoint in a Phase II trial. Following the announcement that once-weekly canvuparatide achieved this endpoint, the company's stock surged 100%, rising from $10.00 on September 19 to $20.00 on September 22. In the Phase II Avail trial (NCT06465108), 63% of patients treated with canvuparatide met the prespecified composite endpoint, maintaining normal albumin-adjusted serum calcium (8.2-10.6 mg/dL) and achieving independence from active vitamin D, over 600 mg/day calcium supplements, and PRN rescue therapy after 12 weeks, compared with 31% of placebo patients reaching the same outcome.
• In May 2025, Bridgebio Pharma, in collaboration with its affiliate Calcilytix Therapeutics, reported that treatment with the investigational therapy encaleret normalized calcium levels in most participants with chronic hypoparathyroidism in a small proof-of-principle study. The company plans to initiate a clinical trial in 2026 that could support encaleret's approval for this condition. Hypoparathyroidism is characterized by abnormally low parathyroid hormone (PTH) levels, a hormone produced by the parathyroid glands that regulates calcium balance in the body. As a result, patients often experience hypocalcemia, or low calcium levels.
• In March 2025, UK-based AstraZeneca's recently acquired rare disease therapy achieved its primary endpoint in a Phase III study involving patients with chronic hypoparathyroidism. In the Calypso trial (NCT05778071), the investigational drug eneboparatide-a parathyroid hormone (PTH) receptor 1 agonist-successfully met the main goal of restoring normal albumin-adjusted serum calcium levels while eliminating the need for active vitamin D and oral calcium supplementation.
• In March 2025, MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in novel precision peptide therapies for endocrine and metabolic disorders, has announced the completion of patient enrollment in its Phase 2 AvailTM trial for MBX 2109 (canvuparatide), a parathyroid hormone (PTH) peptide prodrug. Canvuparatide, designed to have a long-acting effect, is being developed for the treatment of chronic hypoparathyroidism (HP).
• In August 2024, US biotechnology firm MBX Biosciences has administered the first dose to a participant in a Phase II trial for MBX 2109, a potential therapy for chronic hypoparathyroidism (HP). The Avail trial is designed as a randomized, double-blind, placebo-controlled study, enrolling 48 adult patients with Hypoparathyroidism.
• In August 2024, Ascendis Pharma has received approval from the US Food and Drug Administration (FDA) for its drug YORVIPATH (palopegteriparatide) to treat hypoparathyroidism in adults. Hypoparathyroidism is a rare endocrine disorder marked by inadequate levels of parathyroid hormone, which impacts various organs. YORVIPATH, a prodrug of parathyroid hormone (PTH[1-34]), is given once daily.

Hypoparathyroidism Overview
Hypoparathyroidism is a rare endocrine disorder characterized by insufficient production of parathyroid hormone (PTH) from the parathyroid glands. PTH is crucial for regulating calcium and phosphorus levels in the body. The deficiency of PTH leads to low calcium levels (hypocalcemia) and high phosphorus levels (hyperphosphatemia), resulting in symptoms such as muscle cramps, tingling in the extremities, fatigue, and in severe cases, seizures or cardiac issues. The condition can be caused by surgical removal of the parathyroid glands, autoimmune disorders, genetic factors, or idiopathic reasons. Treatment typically involves calcium and vitamin D supplementation to manage symptoms and maintain normal calcium levels.

Get a Free Sample PDF Report to know more about Hypoparathyroidism Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/hypoparathyroidism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Hypoparathyroidism Drugs Under Different Phases of Clinical Development Include:
• TRANSCON PTH (palopegteriparatide): Ascendis Pharma
• Encaleret (BBP-305/CLTX-305): Bridgebio/Calcilytix Therapeutics
• AZP-3601 (eneboparatide): Amolyt Pharma
• MBX 2109: MBX Bioscience
• AMOR-1: Amorphical Ltd.
• EBP05: Entera Bio Ltd.
• TransCon PTH: Visen Pharmaceuticals

Hypoparathyroidism Route of Administration
Hypoparathyroidism pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Hypoparathyroidism Molecule Type
Hypoparathyroidism Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Hypoparathyroidism Pipeline Therapeutics Assessment
• Hypoparathyroidism Assessment by Product Type
• Hypoparathyroidism By Stage and Product Type
• Hypoparathyroidism Assessment by Route of Administration
• Hypoparathyroidism By Stage and Route of Administration
• Hypoparathyroidism Assessment by Molecule Type
• Hypoparathyroidism by Stage and Molecule Type

DelveInsight's Hypoparathyroidism Report covers around 10+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Hypoparathyroidism product details are provided in the report. Download the Hypoparathyroidism pipeline report to learn more about the emerging Hypoparathyroidism therapies
https://www.delveinsight.com/sample-request/hypoparathyroidism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Hypoparathyroidism Therapeutics Market include:
Key companies developing therapies for Hypoparathyroidism are - Amgen Inc., Ascendis Pharma A/S, F. Hoffmann-La Roche Ltd, ProLynx, Inc., Extend Biosciences, Inc., Takeda Pharmaceutical Company Limited., Entera Bio Ltd., BionPharma Inc., Teva Pharmaceuticals Ltd., and others.

Hypoparathyroidism Pipeline Analysis:
The Hypoparathyroidism pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Hypoparathyroidism with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hypoparathyroidism Treatment.
• Hypoparathyroidism key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hypoparathyroidism Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hypoparathyroidism market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Hypoparathyroidism drugs and therapies
https://www.delveinsight.com/sample-request/hypoparathyroidism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Hypoparathyroidism Pipeline Market Drivers
• Rising Incidence, Advancements in Research, Increased Awareness, Regulatory Support, Improved Diagnostic Techniques, are some of the important factors that are fueling the Hypoparathyroidism Market.

Hypoparathyroidism Pipeline Market Barriers
• However, High Treatment Costs, Limited Market Size, Complexity of Treatment, Complexity of Treatment, Limited Clinical Data, and other factors are creating obstacles in the Hypoparathyroidism Market growth.

Scope of Hypoparathyroidism Pipeline Drug Insight
• Coverage: Global
• Key Hypoparathyroidism Companies: Ascendis Pharma, Bridgebio/Calcilytix Therapeutics, Amolyt Pharma, MBX Bioscience, Amorphical Ltd., Entera Bio Ltd., Visen Pharmaceuticals, and others
• Key Hypoparathyroidism Therapies: TRANSCON PTH (palopegteriparatide), Encaleret (BBP-305/CLTX-305), AZP-3601 (eneboparatide), MBX 2109, AMOR-1, EBP05, TransCon PTH, and others
• Hypoparathyroidism Therapeutic Assessment: Hypoparathyroidism current marketed and Hypoparathyroidism emerging therapies
• Hypoparathyroidism Market Dynamics: Hypoparathyroidism market drivers and Hypoparathyroidism market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.